340 related articles for article (PubMed ID: 30808674)
21. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
22. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells.
Tsujita Y; Horiguchi A; Tasaki S; Isono M; Asano T; Ito K; Asano T; Mayumi Y; Kushibiki T
Oncol Rep; 2017 Oct; 38(4):2197-2204. PubMed ID: 28849140
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
[TBL] [Abstract][Full Text] [Related]
24. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
Kawahara T; Ishiguro Y; Ohtake S; Kato I; Ito Y; Ito H; Makiyama K; Kondo K; Miyoshi Y; Yumura Y; Hayashi N; Hasumi H; Osaka K; Muraoka K; Izumi K; Teranishi JI; Uemura H; Yao M; Nakaigawa N
BMC Urol; 2018 Nov; 18(1):97. PubMed ID: 30400941
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
[TBL] [Abstract][Full Text] [Related]
26. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
27. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Zhang D; Reyes RM; Osta E; Kari S; Gupta HB; Padron AS; Kornepati AVR; Kancharla A; Sun X; Deng Y; Wu B; Vadlamudi R; Li R; Svatek RS; Curiel TJ
Cancer Med; 2021 Mar; 10(6):2137-2152. PubMed ID: 33626233
[TBL] [Abstract][Full Text] [Related]
28. Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Hu W; Ma Y; Zhao C; Yin S; Hu H
Mol Carcinog; 2021 Nov; 60(11):746-757. PubMed ID: 34411338
[TBL] [Abstract][Full Text] [Related]
29. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
Yan F; Pang J; Peng Y; Molina JR; Yang P; Liu S
PLoS One; 2016; 11(9):e0162925. PubMed ID: 27610620
[TBL] [Abstract][Full Text] [Related]
30. CKS1B promotes cell proliferation and invasion by activating STAT3/PD-L1 and phosphorylation of Akt signaling in papillary thyroid carcinoma.
Wang H; Zhang Z; Yan Z; Ma S
J Clin Lab Anal; 2021 Jan; 35(1):e23565. PubMed ID: 32960462
[TBL] [Abstract][Full Text] [Related]
31. CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.
Xiu W; Luo J
BMC Immunol; 2021 Jan; 22(1):3. PubMed ID: 33407095
[TBL] [Abstract][Full Text] [Related]
32. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Sumimoto H; Takano A; Teramoto K; Daigo Y
PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
[TBL] [Abstract][Full Text] [Related]
33. Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines.
Ma C; Horlad H; Pan C; Yano H; Ohnishi K; Fujiwara Y; Matsuoka M; Lee A; Niidome T; Yamanaka R; Takeya M; Komohara Y
J Clin Exp Hematop; 2017 Jul; 57(1):21-25. PubMed ID: 28496056
[TBL] [Abstract][Full Text] [Related]
34. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
[TBL] [Abstract][Full Text] [Related]
35. Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism.
Sellam LS; Zappasodi R; Chettibi F; Djennaoui D; Yahi-Ait Mesbah N; Amir-Tidadini ZC; Touil-Boukoffa C; Ouahioune W; Merghoub T; Bourouba M
Arch Biochem Biophys; 2020 Sep; 690():108479. PubMed ID: 32679194
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Song TL; Nairismägi ML; Laurensia Y; Lim JQ; Tan J; Li ZM; Pang WL; Kizhakeyil A; Wijaya GC; Huang DC; Nagarajan S; Chia BK; Cheah D; Liu YH; Zhang F; Rao HL; Tang T; Wong EK; Bei JX; Iqbal J; Grigoropoulos NF; Ng SB; Chng WJ; Teh BT; Tan SY; Verma NK; Fan H; Lim ST; Ong CK
Blood; 2018 Sep; 132(11):1146-1158. PubMed ID: 30054295
[TBL] [Abstract][Full Text] [Related]
37. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells.
Chen RJ; Ho YS; Guo HR; Wang YJ
Toxicol Sci; 2010 May; 115(1):118-30. PubMed ID: 20106947
[TBL] [Abstract][Full Text] [Related]
38. Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
Wang YF; Liu F; Sherwin S; Farrelly M; Yan XG; Croft A; Liu T; Jin L; Zhang XD; Jiang CC
J Invest Dermatol; 2018 Apr; 138(4):922-932. PubMed ID: 29174371
[TBL] [Abstract][Full Text] [Related]
39. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
[TBL] [Abstract][Full Text] [Related]
40. Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity.
Wang J; Huang F; Jiang C; Chi P
Med Sci Monit; 2020 Apr; 26():e915854. PubMed ID: 32343679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
